✦ LIBER ✦

SAFETY AND TOLERABILITY OF GLIAL GROWTH FACTOR 2 IN PATIENTS WITH CHRONIC HEART FAILURE: A PHASE I SINGLE DOSE ESCALATION STUDY

✍ Scribed by Lenihan, Daniel J.; Anderson, Sarah; Geisberg, Carrie; Caggiano, Anthony; Eisen, Andrew; Brittain, Evan; Muldowney III, James A.S.; Mendes, Lisa; Sawyer, Douglas

Book ID: 122934157
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 151 KB
Volume: 61
Category: Article
ISSN: 1558-3597
DOI: 10.1016/S0735-1097(13)60707-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

EVALUATION OF CARDIAC FUNCTION IN SYMPTO

EVALUATION OF CARDIAC FUNCTION IN SYMPTOMATIC HEART FAILURE PATIENTS IN A SINGLE INFUSION, PHASE 1, DOSE ESCALATION STUDY OF GLIAL GROWTH FACTOR 2

✍ Brittain, Evan; Muldowney, James; Geisberg, Carrie; Caggiano, Anthony; Eisen, An 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 288 KB

A Phase 1–2 Dose-Escalating Study Evalua

A Phase 1–2 Dose-Escalating Study Evaluating the Safety and Tolerability of Istaroxime and Specific Effects on Electrocardiographic and Hemodynamic Parameters in Patients with Chronic Heart Failure with Reduced Systolic Function

✍ Jalal K. Ghali; William B. Smith; Guillermo Torre-Amione; William Haynos; Barry 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 963 KB

A phase I dose-escalation study to evalu

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

✍ Desar, I M E; Timmer-Bonte, J N H; Burger, D M; van der Graaf, W T A; van Herpen 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 349 KB

A phase I/II dose escalating trial evalu

A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in patients chronically infected with HBV

✍ P. Marcellin; G.K.K. Lau; H. Mommeja-Marin; S. Sacks; D. Sereni; J.P. Bronowicki 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Intracoronary basic fibroblast growth fa

Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study

✍ Roger J Laham; Nicholas A Chronos; Marilyn Pike; Mark E Leimbach; James E Udelso 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 339 KB

A phase I dose-finding, safety and toler

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies

✍ Cohen, Roger B.; Aamdal, Steinar; Nyakas, Marta; Cavallin, Maria; Green, Darron; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 302 KB